A phase I and pharmacokinetic study of intravenous vinzolidine

Charles W. Taylor, Sydney E. Salmon, Winston G. Satterlee, Aurelia B. Robertone, Thomas M. McCloskey, Mark T. Holdsworth, Patricia M. Plezia, David S Alberts

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The semi-synthetic vinca alkaloid vinzolidine was administered to advanced cancer patients as an intravenous bolus on a three day schedule every 21 days. Forty-two patients were treated in this phase I trial. Five partial remissions (breast-1, melanoma-2, renal cancer-2) were seen in 30 evaluable patients. The dose limiting toxicities were myelosuppression and neuropathy. Erratic myelosuppression from course to course within the same patient as seen in previous trials with oral vinzolidine, was not observed with the intravenous formulation. The measured pharmacokinetic parameters conformed best to a 2-compartment model with a mean terminal half-life of 23 hours. The anti-tumor activity observed during this phase I trial and acceptable toxicity provide the basis for initiating phase II studies in selected forms of cancer.

Original languageEnglish (US)
JournalInvestigational New Drugs
Volume8
Issue number1 Supplement
DOIs
StatePublished - Mar 1990

Fingerprint

Pharmacokinetics
Vinca Alkaloids
Neoplasms
Kidney Neoplasms
Half-Life
Melanoma
Appointments and Schedules
Breast
vinzolidine

Keywords

  • melanoma
  • pharmacokinetics
  • phase I
  • renal cancer
  • vinzolidine

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Cite this

Taylor, C. W., Salmon, S. E., Satterlee, W. G., Robertone, A. B., McCloskey, T. M., Holdsworth, M. T., ... Alberts, D. S. (1990). A phase I and pharmacokinetic study of intravenous vinzolidine. Investigational New Drugs, 8(1 Supplement). https://doi.org/10.1007/BF00171984

A phase I and pharmacokinetic study of intravenous vinzolidine. / Taylor, Charles W.; Salmon, Sydney E.; Satterlee, Winston G.; Robertone, Aurelia B.; McCloskey, Thomas M.; Holdsworth, Mark T.; Plezia, Patricia M.; Alberts, David S.

In: Investigational New Drugs, Vol. 8, No. 1 Supplement, 03.1990.

Research output: Contribution to journalArticle

Taylor, CW, Salmon, SE, Satterlee, WG, Robertone, AB, McCloskey, TM, Holdsworth, MT, Plezia, PM & Alberts, DS 1990, 'A phase I and pharmacokinetic study of intravenous vinzolidine', Investigational New Drugs, vol. 8, no. 1 Supplement. https://doi.org/10.1007/BF00171984
Taylor CW, Salmon SE, Satterlee WG, Robertone AB, McCloskey TM, Holdsworth MT et al. A phase I and pharmacokinetic study of intravenous vinzolidine. Investigational New Drugs. 1990 Mar;8(1 Supplement). https://doi.org/10.1007/BF00171984
Taylor, Charles W. ; Salmon, Sydney E. ; Satterlee, Winston G. ; Robertone, Aurelia B. ; McCloskey, Thomas M. ; Holdsworth, Mark T. ; Plezia, Patricia M. ; Alberts, David S. / A phase I and pharmacokinetic study of intravenous vinzolidine. In: Investigational New Drugs. 1990 ; Vol. 8, No. 1 Supplement.
@article{6c6805c99b68418f92a657c1ef1e7694,
title = "A phase I and pharmacokinetic study of intravenous vinzolidine",
abstract = "The semi-synthetic vinca alkaloid vinzolidine was administered to advanced cancer patients as an intravenous bolus on a three day schedule every 21 days. Forty-two patients were treated in this phase I trial. Five partial remissions (breast-1, melanoma-2, renal cancer-2) were seen in 30 evaluable patients. The dose limiting toxicities were myelosuppression and neuropathy. Erratic myelosuppression from course to course within the same patient as seen in previous trials with oral vinzolidine, was not observed with the intravenous formulation. The measured pharmacokinetic parameters conformed best to a 2-compartment model with a mean terminal half-life of 23 hours. The anti-tumor activity observed during this phase I trial and acceptable toxicity provide the basis for initiating phase II studies in selected forms of cancer.",
keywords = "melanoma, pharmacokinetics, phase I, renal cancer, vinzolidine",
author = "Taylor, {Charles W.} and Salmon, {Sydney E.} and Satterlee, {Winston G.} and Robertone, {Aurelia B.} and McCloskey, {Thomas M.} and Holdsworth, {Mark T.} and Plezia, {Patricia M.} and Alberts, {David S}",
year = "1990",
month = "3",
doi = "10.1007/BF00171984",
language = "English (US)",
volume = "8",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "1 Supplement",

}

TY - JOUR

T1 - A phase I and pharmacokinetic study of intravenous vinzolidine

AU - Taylor, Charles W.

AU - Salmon, Sydney E.

AU - Satterlee, Winston G.

AU - Robertone, Aurelia B.

AU - McCloskey, Thomas M.

AU - Holdsworth, Mark T.

AU - Plezia, Patricia M.

AU - Alberts, David S

PY - 1990/3

Y1 - 1990/3

N2 - The semi-synthetic vinca alkaloid vinzolidine was administered to advanced cancer patients as an intravenous bolus on a three day schedule every 21 days. Forty-two patients were treated in this phase I trial. Five partial remissions (breast-1, melanoma-2, renal cancer-2) were seen in 30 evaluable patients. The dose limiting toxicities were myelosuppression and neuropathy. Erratic myelosuppression from course to course within the same patient as seen in previous trials with oral vinzolidine, was not observed with the intravenous formulation. The measured pharmacokinetic parameters conformed best to a 2-compartment model with a mean terminal half-life of 23 hours. The anti-tumor activity observed during this phase I trial and acceptable toxicity provide the basis for initiating phase II studies in selected forms of cancer.

AB - The semi-synthetic vinca alkaloid vinzolidine was administered to advanced cancer patients as an intravenous bolus on a three day schedule every 21 days. Forty-two patients were treated in this phase I trial. Five partial remissions (breast-1, melanoma-2, renal cancer-2) were seen in 30 evaluable patients. The dose limiting toxicities were myelosuppression and neuropathy. Erratic myelosuppression from course to course within the same patient as seen in previous trials with oral vinzolidine, was not observed with the intravenous formulation. The measured pharmacokinetic parameters conformed best to a 2-compartment model with a mean terminal half-life of 23 hours. The anti-tumor activity observed during this phase I trial and acceptable toxicity provide the basis for initiating phase II studies in selected forms of cancer.

KW - melanoma

KW - pharmacokinetics

KW - phase I

KW - renal cancer

KW - vinzolidine

UR - http://www.scopus.com/inward/record.url?scp=0025285257&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025285257&partnerID=8YFLogxK

U2 - 10.1007/BF00171984

DO - 10.1007/BF00171984

M3 - Article

C2 - 2380017

AN - SCOPUS:0025285257

VL - 8

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 1 Supplement

ER -